Placebo effect characteristics observed in a single, international, longitudinal study in Huntington's disease.

Cubo, E.; González, M.; Puerto, I. d.; J. G., De; Arconada, O. F.; Trejo, J. M.; Zangerl, A; Seppi, K; Wenning, G; Poewe, W; Foeldy, D; Auff, E; Schober, T; Wenzel, K; Ott, E; Walli, J; Leblhuber, F; Dürr, A; Bloch, F; Messouak, O; Tallaksen, C; Dubois, B; Guillamo, Js; Bachoud Lévi, Ac; Engles, A; Krystkowiak, P; Destée, A; Memin, A; Thibaut Tanchou, S; Pasquier, F; Azulay, Jp; Demonet, Jf; Galitzky, M; Rascol, O; Mollion, H; Broussolle, E; Madigand, M; Lallement, F; Goizet, C; Tison, F; Arguillère, S; Viallet, F; Bakchine, S; Khoris, J; Pages, M; Camu, W; Resch, F; Hannequin, D; Durif, F; Saudeau, D; Autret, A; Andrich, J; Saft, C; Kraus, Ph; Przuntek, H; Ecker, D; Kramer, B; Landwehrmeyer, Gb; Ludolph, Ac; Priller, J; Meierkord, H; Kuznik, D; Dose, M; Squitieri, F; Albanese, A; Abbruzzese, G; Filla, Alessandro; van de Warrenburg, B; de Jong, D; Kremer, H; van Vugt, J; Grimbergen, Y; Roos, R; Gawel, M; Janik, P; Kowalczys, H; Pilczuk, B; Kwiecinski, H; Świat, M; Ochudło, S; Modestowicz, R; Niezgoda, A; Łukasik, M; Lukasik, M; de Yébenes, Jg; García Ruiz, P; Descals, Am; Rojo, A; Fontán, A; Hernández, J; Cantarero, S; Fanjul, S; Alegre, J; Roldán, Sg; Mateo, D; Burguera, Ja; Solis, P; Calopa, M; Jaumà, S; Bas, J; Tolosa, E; Muñoz, Je; Gámez, J; Cervera, C; Zarranz, Jj; Lezcano, E; Gómez, Jc; Chacón, J; Dinca, L; Gamero, Ma; Redondo, L; Castro, A; Sesar, A; López del Val, J; López, E; Ríos, C; Castillio, V; Burgunder, Jm; Nirkko, A; Kälin, A; Vingerhoets, F; Wider, C.

doi:10.1002/mds.24062

Classically, clinical trials are based on the placebo-control design. Our aim was to analyze the placebo effect in Huntington's disease.Placebo data were obtained from an international, longitudinal, placebo-controlled trial for Huntington's disease (European Huntington's Disease Initiative Study Group). One-hundred and eighty patients were evaluated using the Unified Huntington Disease Rating Scale over 36 months. A placebo effect was defined as an improvement of at least 50\% over baseline scores in the Unified Huntington Disease Rating Scale, and clinically relevant when at least 10\% of the population met it.Only behavior showed a significant placebo effect, and the proportion of the patients with placebo effect ranged from 16\% (first visit) to 41\% (last visit). Nondepressed patients with better functional status were most likely to be placebo-responders over time.In Huntington's disease, behavior seems to be more vulnerable to placebo than overall motor function, cognition, and function

Placebo effect characteristics observed in a single, international, longitudinal study in Huntington's disease / Cubo, E.; González, M.; Puerto, I. d.; De, J. G.; Arconada, O. F.; Trejo, J. M.; Zangerl, A; Seppi, K; Wenning, G; Poewe, W; Foeldy, D; Auff, E; Schober, T; Wenzel, K; Ott, E; Walli, J; Leblhuber, F; Dürr, A; Bloch, F; Messouak, O; Tallaksen, C; Dubois, B; Guillamo, Js; Bachoud Lévi, Ac; Engles, A; Krystkowiak, P; Destée, A; Memin, A; Thibaut Tanchou, S; Pasquier, F; Azulay, Jp; Demonet, Jf; Galitzky, M; Rascol, O; Mollion, H; Broussolle, E; Madigand, M; Lallement, F; Goizet, C; Tison, F; Arguillère, S; Viallet, F; Bakchine, S; Khoris, J; Pages, M; Camu, W; Resch, F; Hannequin, D; Durif, F; Saudeau, D; Autret, A; Andrich, J; Saft, C; Kraus, Ph; Przuntek, H; Ecker, D; Kramer, B; Landwehrmeyer, Gb; Ludolph, Ac; Priller, J; Meierkord, H; Kuznik, D; Dose, M; Squitieri, F; Albanese, A; Abbruzzese, G; Filla, Alessandro; van de Warrenburg, B; de Jong, D; Kremer, H; van Vugt, J; Grimbergen, Y; Roos, R; Gawel, M; Janik, P; Kowalczys, H; Pilczuk, B; Kwiecinski, H; Świat, M; Ochudło, S; Modestowicz, R; Niezgoda, A; Łukasik, M; Lukasik, M; de Yébenes, Jg; García Ruiz, P; Descals, Am; Rojo, A; Fontán, A; Hernández, J; Cantarero, S; Fanjul, S; Alegre, J; Roldán, Sg; Mateo, D; Burguera, Ja; Solis, P; Calopa, M; Jaumà, S; Bas, J; Tolosa, E; Muñoz, Je; Gámez, J; Cervera, C; Zarranz, Jj; Lezcano, E; Gómez, Jc; Chacón, J; Dinca, L; Gamero, Ma; Redondo, L; Castro, A; Sesar, A; López del Val, J; López, E; Ríos, C; Castillio, V; Burgunder, Jm; Nirkko, A; Kälin, A; Vingerhoets, F; Wider, C.. - In: MOVEMENT DISORDERS. - ISSN 0885-3185. - ELETTRONICO. - 27:(2012), pp. 439-442. [10.1002/mds.24062]